Europe Cell & Gene Therapy Market Insights 2024-2029: Rising use of CGT Products for Disease Care, Funding Support in Europe for CGTs
June 20, 2024 04:06 ET
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Europe Cell & Gene Therapy Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.The Europe Cell &...
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
June 18, 2024 16:48 ET
|
Longeveron
Longeveron raises $4.4 Million in gross proceeds from warrant exercise transaction to fund development of its cellular therapy Lomecel-B
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
June 17, 2024 09:00 ET
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress
June 14, 2024 07:30 ET
|
Wugen
Wugen Presents Data at European Hematology Association (EHA) 2024 Hybrid Congress
Neo Antigen T-cell Therapy Pipeline Insights for 2024: A Comprehensive Clinical Development Scenario
June 14, 2024 06:56 ET
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "Neo Antigen T-cell Therapy - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.In the dynamic landscape of cancer...
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
June 12, 2024 07:00 ET
|
KSQ
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered eTIL® Therapy
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
June 11, 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
June 11, 2024 09:00 ET
|
Longeveron
Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.
Cell Culture Market Is Expected To Reach A Revenue Of USD 80.3 Bn By 2033, At 11.0% CAGR: Dimension Market Research
June 10, 2024 10:53 ET
|
Dimension Market Research
New York, June 10, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Cell Culture Market size is expected to reach USD 31.4 billion by 2024 and is further anticipated to reach USD 80.3 billion...
Translational Regenerative Medicine Market Set to Surpass $77 Billion in 2024
June 06, 2024 04:10 ET
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Translational Regenerative Medicine Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.Overall world revenue for the...